2021 Volume 38 Issue 5 Pages 719-722
Recent advances and new findings relating to multiple sclerosis (MS) and other inflammatory disorders in the central nervous system were reviewed. The following topics were discussed : the association between disease modifying therapy (DMT) of MS and coronavirus infectious disease–19 (COVID–19), the association between initial DMT and MS disability progression, the efficacy of extended interval dosing of rituximab in treatment for RRMS, the efficacy and safety of ofatumumab for RRMS, the characteristic relapse patterns of neuromyelitis optica spectrum disorder (NMOSD), the efficacy and safety of satralizumab monotherapy for relapse prevention of NMOSD, the characteristic MRI findings of myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), the pathological characteristics of MOGAD, and the use of rituximab for relapse prevention of NMOSD and MOGAD.
